Rare Cancers Europe is delighted to announce the election of its new Steering Committee. Elected for a mandate of 2 years, the Steering Committee ensures representation of the views of the different stakeholder groups comprising the RCE partnership.
As a multi-stakeholder partnership bringing together patient groups, education providers, research groups, scientific societies and healthcare providers, and industry, it is crucial that Rare Cancers Europe’s activities reflect the priorities of the entire rare cancer community. To ensure that this happens, the RCE Steering Committee includes one representative per stakeholder group, allowing a full range of perspectives in RCE’s decision-making.
RCE would also like to take this opportunity to thank the members of the previous Steering Committee for their service. Their effort and collaboration ensured that RCE continued to raise awareness around the unique set of challenges faced by rare cancer community, as well as keeping the topic firmly on the EU’s policy agenda.
RCE congratulates the newly elected members of the RCE Steering Committee:
Alexandru Eniu, European School of Oncology (ESO), representing educational providers:
Alexandru’s previous involvement with ESMO and the American Society of Clinical Oncology (ASCO) has included public policy work at both global and EU levels. He has previously served as a member of the ESMO Board, the Chair of the ESMO Global Policy Committee, as a member of the ESMO European Policy Committee and as a Chair of the ASCO International Affairs Committee.
Ariane Weinman, The European Organisation for Rare Diseases (EURORDIS), representing patient groups:
As an active RCE member, Ariane has worked on the EU Joint Action on Rare Cancers (JARC) and coordinated with patient representatives on the recommendations for patients' involvement in research and care. As a Steering Committee member, she will contribute to the translation of the recommendations set out in the Rare Cancer Agenda 2030 and in the European Parliament’s report “Strengthening Europe in the fight against Cancer - towards a comprehensive and coordinated strategy” into concrete measures for rare cancer patients, together with patient organisations and the wider rare cancers community.
Denis Lacombe, European Organisation for Research and Treatment of Cancer (EORTC), representing research groups:
Rare cancers have a high priority on the EORTC agenda, given its role as the leading cancer clinical research organisation. Denis’s active engagement will continue EORTC’s involvement in the Steering Committee and help ensure that rare cancers are at the top of the European policy agenda.
Ivana Cattaneo, Novartis, representing industry:
RCE is delighted that Ivana will continue to serve on the Steering Committee and contribute to tackling the challenges presented by rare cancers through RCE’s collaborative approach. This form of multi-stakeholder partnership allows RCE to pursue its mission of raising awareness on the specificities of rare cancers while providing an opportunity for collaboration amongst a wide range of stakeholders.
Umberto Ricardi, European Society Radiation Oncology (ESTRO), representing scientific societies and healthcare providers:
Thanks to Umberto’s membership of the Steering Committee, ESTRO will continue its close involvement in RCE’s activities and focus its contributions on fostering collaboration amongst oncology disciplines. This is in line with the ESTRO vision 2030 “Radiation Oncology, Optimal Health for All, Together” and is a fundamental element of modern oncology, a concept that becomes even more strategic when dealing with rare cancers.